Related references
Note: Only part of the references are listed.Prognostic impact of protein kinase C β II expression in R-CHOP-treated diffuse large B-cell lymphoma patients
Sari Riihijarvi et al.
MODERN PATHOLOGY (2010)
Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab
Kritika Chaiwatanatorn et al.
LEUKEMIA & LYMPHOMA (2009)
Diffuse Large B-Cell Lymphoma
Jonathan W. Friedberg et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2008)
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma
Michael J. Robertson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The protein kinase Cβ-selective inhibitor, enzastaurin (LY317615.HCI), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts
JR Graff et al.
CANCER RESEARCH (2005)
Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR
A Dutton et al.
JOURNAL OF PATHOLOGY (2005)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
MA Shipp et al.
NATURE MEDICINE (2002)
Share Paper
